Skip to search formSkip to main contentSkip to account menu

regadenoson

Known as: (1-(9-(3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl)-6-aminopurin-2-yl)pyrazol-4-yl)-N-methylcarboxamide, Adenosine, 2-(4-((methylamino)carbonyl)-1H-pyrazol-1-yl)- 
An adenosine derivative and selective A2A adenosine receptor agonist with coronary vasodilating activity. Upon administration, regadenoson… 
National Institutes of Health

Related topics

Related topics

6 relations

Broader (3)

Adenosine A2 Receptor AgonistsPurinesPyrazoles
Adenosine Receptor Agonists [MoA]regadenoson 0.08 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [LEXISCAN]

Narrower (1)

CVT 3146

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Abstracts of Original Contributions ASNC2016 The 21st Annual Scientific Session of the American Society of Nuclear Cardiology
s of Original Contributions ASNC2016 The 21st Annual Scientific Session of the American Society of Nuclear Cardiology September… 
2016
2016
Bulging at the Root: An Inflammatory Tale
Information about a real patient is presented in stages (boldface type) to an expert clinician (Dr Bhatt), who responds to the… 
Review
2015
Review
2015
Regadenoson — Overview of Applications in Cardiology
Coronary artery disease is a leading cause of morbidity and mortality in developed countries. According to a Center for Disease… 
2014
2014
Stable solid forms of Regadenoson
The invention provides stable solid forms of Regadenoson. A process for the preparation of the amorphous form of Regadenoson of… 
2013
2013
Regadenoson pharmacologic rubidium-82 PET: A comparison of quantitative perfusion and function to dipyridamole
BackgroundDipyridamole is used for stress 82rubidium chloride (82RbCl) PET because of its long hyperemic duration. Regadenoson… 
2013
2013
A process for the preparation of regadenoson
The present invention provides novel processes for the preparation of regadenoson having the formula (I). In some embodiments… 
2013
2013
Regadenoson - selektivní A2A adenozin pro farmakologický zátěžový test v nukleární kardiologii
Prezentujeme dvě kazuistiky dokumentujici výhody využiti selektivniho A2A adenozinu (regadenoson) při zatěžových testech v… 
2013
2013
Preparation method for regadenoson
The invention discloses a preparation method for regadenoson, belonging to the field of pharmaceutical chemistry. The preparation… 
2012
2012
Abstract 17636: Safety and Tolerability of Regadenoson Stress CMR
Background & Objective: Regadenoson binds selectively to the A(2A) receptor to promote coronary vasodilation during stress… 
2008
2008
FDA approves pharmacologic stress agent.
CV Therapeutics Inc. and Astellas Pharma US Inc. on April 10 announced that FDA approved the marketing of regadenoson injection…